Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,981 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib].
Zhou Q, Lu S, Li Y, Jia F, Li G, Hong Z, Lu Y, Fan Y, Zhou J, Liu Z, Li J, Wu YL; Chinese Thoracic Oncology Group (CTONG); Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup. Zhou Q, et al. Among authors: lu y, lu s. Zhongguo Fei Ai Za Zhi. 2022 Aug 20;25(8):555-566. doi: 10.3779/j.issn.1009-3419.2022.101.39. Zhongguo Fei Ai Za Zhi. 2022. PMID: 36002192 Free PMC article. Chinese.
[Safety analysis of ambulatory chemotherapy in lung cancer].
Feng Y, Lu S, Song Z, Xu L, Shi Y, Chen Z. Feng Y, et al. Among authors: lu s. Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):713-6. doi: 10.3779/j.issn.1009-3419.2010.07.10. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20673488 Free PMC article. Chinese.
[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
Zhang XC, Lu S, Zhang L, Wang CL, Cheng Y, Li GD, Mok T, Huang C, Liu XQ, Wang J, Wang MZ, Zhang YP, Zhou JY, Zhou XY, Lin DM, Yang JJ, Li H, Chen HQ, Zhong WZ, Wu YL. Zhang XC, et al. Among authors: lu s. Zhonghua Bing Li Xue Za Zhi. 2013 Jun;42(6):402-6. doi: 10.3760/cma.j.issn.0529-5807.2013.06.012. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 24060077 Chinese. No abstract available.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Among authors: lu s. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.
15,981 results
You have reached the last available page of results. Please see the User Guide for more information.